ReviewJournal of clinical microbiology2016
Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.
Review in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Melioidosis in companion animals: Analysis of 45 Australian cases (24 dogs; 21 cats) from 1997 to 2025 and a brief review of the animal and human literature.Australian veterinary journal · 2026Review
- Human infections caused by pathogenic Burkholderia: current clinical challenges and future perspectives.Infection · 2026Review
- Disseminated Melioidosis from a Ruptured Infective Aortic Aneurysm and Pedal Ulcers to Septic Arthritis and Osteomyelitis: A Case Report.Vascular specialist international · 2025Article
- Postexposure Antimicrobial Drug Therapy in Goats Infected with Burkholderia pseudomallei.Emerging infectious diseases · 2025Article
- Clinical and Microbiological Profile of Melioidosis in a Tertiary Care Hospital in Kerala, India.The American journal of tropical medicine and hygiene · 2025Article
- Co-Infections and Their Prognostic Impact on Melioidosis Mortality: A Systematic Review and Individual Patient Data Meta-Analysis.Epidemiologia (Basel, Switzerland) · 2025Review
- Melioidosis vaccines: recent advances and future directions.Frontiers in immunology · 2025Review
- Review
- Characteristic of pancreatic involvement in melioidosis: Case report and literature review.Heliyon · 2024Article
- A Rare Case of Melioidosis in the Bronx.Cureus · 2024Article
- Nucleic Acid Amplification Free-QCM-DNA Biosensor for Burkholderia pseudomallei Detection.Current microbiology · 2023Article
- Serodiagnosis of Abdominal Abscess Caused byInfection and drug resistance · 2023Article
- Monitoring Laboratory Occupational Exposures toApplied biosafety : journal of the American Biological Safety Association · 2022Article
- A Case ofOpen forum infectious diseases · 2022Article
- The Innate Immune Response in the Marmoset during the Acute Pneumonic Disease Caused by Burkholderia pseudomallei.Infection and immunity · 2022Article
- Article
- Aortic endograft infection secondary toJournal of vascular surgery cases and innovative techniques · 2021Article
- Silver Nanoparticles Enhance Antimicrobial Efficacy of Antibiotics and Restore That Efficacy against the Melioidosis Pathogen.Antibiotics (Basel, Switzerland) · 2021Article
- A rare case: first description of a patient with melioidosis presenting with pericardial effusion in Germany.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Article
- Burkholderia pseudomallei Clinical Isolates Are Highly SusceptibleAntimicrobial agents and chemotherapy · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melioidosis is a potentially fatal infection caused by the bacterium Burkholderia pseudomallei Clinical diagnosis of melioidosis can be challenging since there is no pathognomonic clinical syndrome, and the organism is often misidentified by methods used routinely in clinical laboratories. Although the disease is more prevalent in Thailand and northern Australia, sporadic cases may be encountered in areas where it is not endemic, including the United States. Since the organism is considered a tier 1 select agent according to the Centers for Disease Control and Prevention and the U.S. Department of Agriculture Animal and Plant Health Inspection Service, clinical laboratories must be proficient at rapidly recognizing isolates suspicious for B. pseudomallei, be able to safely perform necessary rule-out tests, and to refer suspect isolates to Laboratory Response Network reference laboratories. In this minireview, we report a case of melioidosis encountered at our institution and discuss the laboratory challenges encountered when dealing with clinical isolates suspicious for B. pseudomallei or clinical specimens from suspected melioidosis cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.